Lv71
3950 积分 2023-02-21 加入
FIGO-Ⅰ期卵巢透明细胞癌患者预后分析
3个月前
已完结
Ⅰ期卵巢透明细胞癌患者临床病理特点及预后分析——北京协和医院12年临床资料回顾性分析
3个月前
已完结
基于GC-MS探讨肝脏再生代谢变化规律及相关代谢标志物的研究
5个月前
已完结
Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors
9个月前
已完结
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors
9个月前
已完结
The synthesis and evaluation of sulfonamide derivatives target EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
9个月前
已完结
Identification of highly potent 2,4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors
9个月前
已完结
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
9个月前
已完结
Identification of highly potent 2,4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors
9个月前
已完结
柠檬酸钠的特性与应用
10个月前
已完结
Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations
6小时前
待审核
DNA Cassette Exchange in ES Cells Mediated by FLP Recombinase: An Efficient Strategy for Repeated Modification of Tagged Loci by Marker-Free Constructs
14天前
已采纳
Grape-Like Fe3O4 Agglomerates Grown on Graphene Nanosheets for Ultrafast and Stable Lithium Storage
14天前
已采纳
Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7
16天前
已采纳
Abstract ND12: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers
29天前
已采纳
Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC)
30天前
已采纳
Abstract 5680: Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies
30天前
已采纳
ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
1个月前
已采纳
Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer
1个月前
已采纳
The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields
1个月前
已采纳
皖公网安备34019202002308
